Bonerge initiates clinical trial evaluating Urolithin A and Fisetin for age-related sleep disruptions

Bonerge, a nutraceutical innovation leader specializing in senolytic and cellular repair ingredients, has initiated a clinical trial (NCT06990256) to evaluate the effect of StanYouth® Urolithin A and BeFisetin® Fisetin on sleep quality. The 12-week, randomized, placebo-controlled study investigates the ability of these compounds to resynchronize circadian rhythms and improve sleep architecture in adults aged 45 to 70 experiencing subclinical sleep disturbances.

Why is Bonerge testing Urolithin A and Fisetin in a clinical setting for sleep and circadian health applications?

This newly launched study positions Bonerge among a growing set of anti-ageing formulators aiming to move beyond traditional consumer sleep aids by anchoring claims in molecular ageing pathways. According to study documentation, the trial’s primary endpoint is to evaluate improvements in sleep parameters using subjective tools like PSQI and objective measures like actigraphy and polysomnography (PSG). It is also the first study of its kind to combine epigenetic and metabolic biomarker tracking—spanning DNA methylation age, NAD+ levels, and inflammation markers—to define sleep quality in the context of biological ageing.

The trial’s design includes four arms: Urolithin A only, Fisetin only, Urolithin A + Fisetin combination, and placebo. Notably, participants are free of formal insomnia diagnoses, allowing the study to focus on age-related circadian misalignment rather than diagnosed pathology. This reflects a growing hypothesis within the scientific community that mitochondrial dysfunction and cellular senescence are central to sleep disturbances in perimenopausal and ageing individuals.

Institutional sentiment points to rising interest in next-generation nutraceuticals that go beyond melatonin or GABA modulation, with Urolithin A gaining prominence as a circadian rhythm regulator and mitochondrial health enhancer. The inclusion of Fisetin, a senolytic flavonoid, complements this by targeting inflammation and sleep-disruptive senescence.

How does this trial align with Bonerge’s broader strategy in the ageing biology and wellness sector?

Bonerge, headquartered in the United States, has pursued an “ingredient-to-ecosystem” model in the nutraceutical domain. This involves a full lifecycle innovation strategy—spanning compound isolation, mechanistic validation, and eventual clinical translation. The company’s flagship compounds, including StanYouth® Urolithin A and BeFisetin® Fisetin, anchor this platform, alongside secondary pipeline assets like L-Ergothioneine, PQQ Disodium, and S-Equol.

The current study reinforces Bonerge’s ambition to position its proprietary compounds not as functional food additives but as biologically actionable anti-ageing agents, particularly those targeting circadian homeostasis, NAD+ metabolism, and hormonal balance.

Historically, sleep quality products in the supplement space have been dominated by symptomatic relief agents. However, Bonerge’s formulation roadmap integrates mitochondrial repair, DNA protection, and hormonal sensitivity—elements more commonly associated with bio-gerontology than OTC wellness. This has prompted many institutional observers to categorize Bonerge as an R&D-driven healthspan company, not merely a nutraceutical supplier.

What clinical endpoints and biomarkers is Bonerge using to measure improvements in biological sleep regulation?

The trial incorporates a multi-pronged evaluation methodology:

Sleep Architecture: Measured by PSQI scores, daytime dysfunction scales, and Morningness-Eveningness questionnaires, combined with objective PSG and actigraphy data

Inflammatory & Senescence Markers: Interleukin-6 (IL-6), TNF-α, and immunoglobulin panels to track systemic inflammation and immune responses

Mitochondrial & Epigenetic Health: NAD+ concentration levels, DNA methylation clocks, and circadian protein markers (BMAL1, PER2)

Hormonal & Metabolic Outcomes: Cortisol rhythm profiles, insulin resistance via HOMA-IR, and sex hormone responsiveness—especially relevant for menopausal-related sleep disturbances

This holistic biomarker framework is widely considered a gold standard in translational anti-ageing research. Institutional investors and R&D stakeholders are increasingly demanding such rigor to separate mechanistically validated anti-ageing products from wellness market noise.

According to trial lead Professor Chen, the objective is not merely to extend sleep duration but to recalibrate the body’s internal timekeeping and inflammatory regulation systems—core disturbances seen in ageing.

How is Bonerge leveraging this trial to enhance credibility in the ageing and longevity supplement category?

The nutraceutical sector has long struggled with perception issues stemming from lax regulatory oversight and a flood of non-evidence-based products. By registering this trial on ClinicalTrials.gov and adopting a quadruple-blind, placebo-controlled design, Bonerge addresses a key demand from longevity-focused consumers and institutional buyers: biological credibility.

The company’s shift toward a clinical validation-first model mirrors recent strategic moves by competitors in the healthspan space—especially those focused on NAD+ precursors, senolytics, and mitochondrial enhancers.

Bonerge has also signaled plans to expand partnerships with global academic institutions to broaden the application of Urolithin A across other age-related conditions, including muscle atrophy, cognitive decline, and reproductive senescence. The company is exploring joint ventures in Japan and Europe, where the intersection of cellular senescence and sleep health is receiving heightened regulatory attention.

What are the projected market implications of Bonerge’s clinical focus on sleep and cellular senescence?

Analysts tracking the convergence of ageing biology and consumer wellness suggest that clinically-validated longevity ingredients could disrupt the fragmented sleep aid market. If Bonerge’s trial confirms efficacy in realigning circadian rhythms and reversing subclinical sleep deterioration, it could redefine formulation standards across sleep, menopause support, and mitochondrial health segments.

While the global sleep aid market exceeds $70 billion, very few products are supported by molecular biomarker data or epigenetic endpoints. Bonerge’s initiative is expected to spur copycat trials and broader application of senotherapeutic ingredients in functional food and pharma-adjacent categories.

Investor interest in Bonerge has remained strong, particularly as regulators in Asia and North America tighten disclosure norms for health claims. Bonerge’s decision to adopt FDA-registered trial protocols positions it well to enter regulated therapeutic or prescription-grade nutraceutical pathways, particularly in regions pursuing hybrid categories between supplements and drugs.

What is the future outlook for Bonerge’s ingredient ecosystem and clinical research expansion?

Following this trial, Bonerge aims to launch additional studies in the fields of reproductive health, cognitive clarity, and immune rejuvenation, applying the same multi-biomarker and systems biology approach. The firm’s roadmap includes trials involving combinations of Urolithin A, L-Ergothioneine, and S-Equol, particularly for menopausal sleep disorders and telomere shortening mitigation.

The American anti-ageing ingredient innovator also continues to court licensing and co-formulation partnerships with nutraceutical firms in Europe, North America, and Japan, where regulatory appetite for clinically backed formulations is highest.

Looking forward, institutional analysts expect Bonerge to evolve beyond ingredient production into a platform-based model, offering bio-validated formulation kits and diagnostic integrations for longevity-focused clinics and wellness chains.